Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04986202 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 711
- Enrollment target
NCT04986202 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 711 participants.
The verdict
NCT04986202, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 711 participants
- Enrollment target
Study Summary
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fraction \> 40%. The study will consist of 2 separate parts, Part A and Part B, approximately 660 participants will be randomised in Part A, 820 in Part B.
Interventions
- OTHER Placebo
- DRUG AZD4831
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 711 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2024-03-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04986202
The ClinicalTrials.gov registry entry for NCT04986202 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 711 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04986202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04986202 about?
NCT04986202 is a clinical study titled "Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%". This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fraction \> 40%. The study will consist of 2 sep...
What is the current status of trial NCT04986202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 711 participants. The study started on 2021-06-30. Estimated completion is 2024-03-27.
What interventions are being tested in trial NCT04986202?
The interventions under investigation include: Placebo (OTHER), AZD4831 (DRUG).
Who is sponsoring clinical trial NCT04986202?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.